Baird initiates coverage on Hinge Health stock with Neutral rating

Published 05/09/2025, 10:56
Baird initiates coverage on Hinge Health stock with Neutral rating

Investing.com - Baird initiated coverage on Hinge Health Inc (NYSE:HNGE) with a Neutral rating and a price target of $56.00 on Friday. The digital healthcare company, currently valued at $4.5 billion, has shown strong momentum with a 49% price return over the past six months.

The research firm acknowledged Hinge Health’s compelling product offering that addresses a critical need among payers in reducing musculoskeletal-related costs.

Baird highlighted several positive aspects of the company, including "the attractive market opportunity, robust growth rate, and runway for profitability."

Despite these strengths, the firm expressed caution regarding two key concerns: potential macroeconomic factors weighing on end-market demand and intense industry competition.

Baird noted that these concerns, combined with "already robust investor expectations at this stage," led to its cautious stance on the digital healthcare company.

In other recent news, Hinge Health has seen a series of positive developments following its second-quarter earnings report. The company reported revenue of $139.1 million, surpassing consensus estimates of $125.4 million and marking a 55% year-over-year growth. This strong performance prompted Hinge Health to raise its 2025 revenue and EBIT guidance, with expectations for second-half revenue growth exceeding 40%. Piper Sandler responded to these results by raising its price target for Hinge Health to $70, maintaining an Overweight rating due to the company’s robust technology and commercial strategies. Stifel also increased its price target to $63, citing the company’s significant outperformance relative to market expectations. Additionally, Citizens JMP raised its price target to $65 and maintained a Market Outperform rating, reflecting confidence in Hinge Health’s growth trajectory. These developments follow Citizens JMP’s initiation of coverage with a Market Outperform rating and a price target of $58 after the company’s IPO. These updates highlight the positive sentiment among analysts regarding Hinge Health’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.